Free Trial
NYSE:CRL

Charles River Laboratories International (CRL) Stock Price, News & Analysis

Charles River Laboratories International logo
$157.12 -0.37 (-0.23%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$157.12 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Charles River Laboratories International Stock (NYSE:CRL)

Key Stats

Today's Range
$156.17
$158.72
50-Day Range
$114.71
$157.50
52-Week Range
$91.86
$254.15
Volume
247,085 shs
Average Volume
1.03 million shs
Market Capitalization
$7.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$171.85
Consensus Rating
Hold

Company Overview

Charles River Laboratories International Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

CRL MarketRank™: 

Charles River Laboratories International scored higher than 81% of companies evaluated by MarketBeat, and ranked 592nd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Charles River Laboratories International has received a consensus rating of Hold. The company's average rating score is 2.19, and is based on 4 buy ratings, 11 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Charles River Laboratories International has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Charles River Laboratories International's stock forecast and price target.
  • Earnings Growth

    Earnings for Charles River Laboratories International are expected to grow by 17.52% in the coming year, from $9.36 to $11.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Charles River Laboratories International is -241.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Charles River Laboratories International is -241.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Charles River Laboratories International has a PEG Ratio of 5.33. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Charles River Laboratories International has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Charles River Laboratories International's valuation and earnings.
  • Percentage of Shares Shorted

    5.38% of the float of Charles River Laboratories International has been sold short.
  • Short Interest Ratio / Days to Cover

    Charles River Laboratories International has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Charles River Laboratories International has recently increased by 7.85%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Charles River Laboratories International does not currently pay a dividend.

  • Dividend Growth

    Charles River Laboratories International does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.38% of the float of Charles River Laboratories International has been sold short.
  • Short Interest Ratio / Days to Cover

    Charles River Laboratories International has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Charles River Laboratories International has recently increased by 7.85%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Charles River Laboratories International has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Charles River Laboratories International this week, compared to 11 articles on an average week.
  • Search Interest

    Only 2 people have searched for CRL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Charles River Laboratories International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $92,407.00 in company stock.

  • Percentage Held by Insiders

    Only 1.30% of the stock of Charles River Laboratories International is held by insiders.

  • Percentage Held by Institutions

    98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Charles River Laboratories International's insider trading history.
Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
3 Reasons to Sell CRL and 1 Stock to Buy Instead
See More Headlines

CRL Stock Analysis - Frequently Asked Questions

Charles River Laboratories International's stock was trading at $184.60 at the beginning of 2025. Since then, CRL stock has decreased by 14.9% and is now trading at $157.12.

Charles River Laboratories International, Inc. (NYSE:CRL) released its quarterly earnings results on Wednesday, May, 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The firm's quarterly revenue was down 2.7% on a year-over-year basis.
Read the conference call transcript
.

Charles River Laboratories International's Board of Directors authorized a stock buyback plan on Wednesday, August 7th 2024, which allows the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 9.6% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's management believes its shares are undervalued.

Charles River Laboratories International subsidiaries include these companies: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and more.

Top institutional investors of Charles River Laboratories International include Confluence Investment Management LLC (0.20%) and Harbor Investment Advisory LLC. Insiders that own company stock include James C Foster, Birgit Girshick, William D Barbo, Joseph W Laplume, Victoria L Creamer, Richard F Wallman, Michael Gunnar Knell, George Massaro and Shannon M Parisotto.
View institutional ownership trends
.

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Home Depot (HD) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/07/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Medical Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:CRL
Employees
20,100
Year Founded
1947

Price Target and Rating

Average Stock Price Target
$171.85
High Stock Price Target
$210.00
Low Stock Price Target
$140.00
Potential Upside/Downside
+9.4%
Consensus Rating
Hold
Rating Score (0-4)
2.19
Research Coverage
16 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
16.79
P/E Growth
5.33
Net Income
$22.20 million
Pretax Margin
0.75%

Debt

Sales & Book Value

Annual Sales
$4.05 billion
Cash Flow
$21.64 per share
Price / Cash Flow
7.26
Book Value
$67.80 per share
Price / Book
2.32

Miscellaneous

Free Float
48,477,000
Market Cap
$7.72 billion
Optionable
Optionable
Beta
1.49

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NYSE:CRL) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners